Prevention

A subcutaneous implantable cardioverter defibrillator was noninferior to a transvenous ICD regarding major ICD-related adverse events in patients indicated for such treatment, according to data from the PRAETORIAN trial presented at the virtual Heart Rhythm Society Annual Scientific Sessions.

Effect of target LDL on secondary stroke prevention.

An intensified support program in addition to conventional care for patients with transient ischemic attack or minor stroke was more successful in achieving secondary prevention targets than conventional care alone.

Treatment with a polypill — generally combining statins, BP-lowering drugs and sometimes aspirin — is not a new concept for CVD. Two recent successful trials have brought the use of a polypill for primary and secondary prevention of CVD into the spotlight again, one of which extended the applicability of the concept to the United States.

PARIS — New data from the SWEDEHEART registry presented at the European Society of Cardiology Congress show that use of statins, antiplatelet therapies and renin-angiotensin-aldosterone system inhibitors yields reduced risk for mortality after CABG.

Alirocumab reduced the risk for major adverse CV events and death in patients with recent ACS and polyvascular disease and in those with CABG after an ACS event, according to two analyses of the ODYSSEY OUTCOMES trial published in the Journal of the American College of Cardiology.